All BullZZ no BearZZ!

[Hedge Starz]

Blackbird International $BBRD Corporation Announces The Acquisition Of Professional Services And Engineering Firm

OAKVILLE, Ontario, April 25, 2012 /PRNewswire/ -- BLACKBIRD INTERNATIONAL CORPORATION (BBRD.PK) announces that it has agreed to acquire Robert Pound Consulting Company, a firm specializing in ISO 9001 and environmental ISO 14001 audits, training and certifications. Robert Pound Consulting (RPC) has evergreen contracts with many of North America's "Blue Chip" organizations, helping them gain compliance and continuous improvements to maintain the certification. Robert Pound and associates has over 15 years of industry experience and aims to supplement the operations and compliance of Blackbird and its divisions. The company will be integrated into Blackbird's Technology and Business Services Division operating under Insight Group Technologies business consulting division. It is expected under the new structure that RPC can leverage Insight's global clients, and it is anticipated that with its technology Robert Pound Consulting will double its sales over the coming year, thereby adding to Blackbird's revenues.
''This acquisition will exponentially increase sales in both operating companies because of cross referencing in our respective client bases,'' sates John Pedder, president. He adds, "We shall also continue in our acquisition mode to give excellent present and future value to our shareholders.''
About Blackbird International Corporation
Blackbird is in the business of developing and implementing software both in the gaming industry as well as in the field of supply chain management. It develops products and provides the installation and the services required by many Fortune 500 clients. Among its clientele for its technology and services include Fosters Beer (Australia), Nestle, Coka Cola, MainFreight (Australia). It is in an acquisition mode in order rapidly become a major firm in this lucrative global market.
Contact:
John Pedder
[e-mail]

[MightySam]

123

[Mr. Smith]

BRGO MAJOR CORRECTION UNDERWAY

$BRGO

10

[Hedge Starz]

Scorpex Inc (SRPX)



BASIC SRPX INFO
Scorpex, Inc. is focused on becoming a leader of hazardous and toxic waste disposal in the Baja Mexico/California region where demand for waste management exceeds capacity. To date, the company has constructed a 10,000 square foot storage facility, water reservoir and septic system, sprinkler system, and security fence and is in the process of developing other necessary infrastructure on its 26-acre site.
Share Structure
Shares Outstanding 155,225,432 a/o Jun 02, 2011
Float 35,133,182 a/o Jun 02, 2011
Authorized Shares 460,000,000 a/o May 17, 2011
Management
CEOJoseph Caywood: Mr. Caywood has successfully owned and operated many businesses since 1989, including an extremely profitable classic car business. Mr. Caywood has invested his own money into various business enterprises including Scorpex International, Inc., where he has spent the last several years developing a toxic and hazardous waste storage, recycling, and disposal site on the perimeter of Ensenada, Mexico.
Interim CFOChene Gardner: Mr. Gardner is also an executive officer and director of Nano Dimensions, Inc. (“NDI”), a filer of reports with the Commission under the Exchange Act.Mr. Gardner was appointed as CEO, CFO and as a director of NDI in July 2007, May 2004, and August 2004, respectively. In addition, he serves as an executive officer and director of Secure Netwerks, Inc., a filer of reports with the Commission under the Exchange Act, and has served in these capacities since March 2004.
Board MemberKenneth Danos: Kenneth I. Denos, age 43, has served as a member of the Board of Equus Total Return, Inc. (NYSE: EQS) and, since June 2010, has served as the Equus Secretary. From August 2007 until June 2009, he was the CEO and President of Equus.
Mr. Denos also serves as Deputy Chairman of the Board of London Pacific & Partners, Inc., an international healthcare and hospitality services company based in London and Los Angeles.
NEWS
Scorpex Announces Acceptance of Urban Impact Study
http://finance.yahoo.com/news/Scorpex-Announces-Acceptance-iw-601456620.html?x=0
Scorpex Accomplishes Key 2011 Business Objectives Far Ahead of Schedule
http://finance.yahoo.com/news/Scorpex-Accomplishes-Key-2011-iw-458655012.html?x=0
Scorpex Granted Federal Permit
http://finance.yahoo.com/news/Scorpex-Granted-Federal-iw-3938494450.html?x=0
Scorpex Receives Multiple Financing Commitments for up to $35 Million
http://finance.yahoo.com/news/UPDATE-Scorpex-Receives-iw-3144814206.html?x=0
Scorpex Engages Accounting Group to Prepare for its Audit
http://finance.yahoo.com/news/Scorpex-Engages-Accounting-bw-2183724522.html?x=0&.v=1
Scorpex Submits Its Urban Impact Study for State and City Permitting
http://finance.yahoo.com/news/Scorpex-Submits-Its-Urban-bw-1529802495.html?x=0&.v=1

for more SRPX headlines go to:
http://finance.yahoo.com/q?s=SRPX.PK&ql=0

[Hedge Starz]

IAGMbuying up iPhone Fitness APP http://finance.yahoo.com/news/InterAmerican-Gaming-to-iw-3950899394.html?x=0&.v=1

[InvestorSuisse]

Agreed! Time to get Allbullsnobears up and running!

[InvestorSuisse]

IENT - Thriller New Media was created in late 2007 by Wild Bill Stealey, who first worked as executives at legendary 1980’s-era game brand/studio/publisher, MicroProse Software. Bill co-founded MicroProse with hall-of-fame game designer, Sid Meier. Wild Bill Stealey has (with a great bunch of other folks, to be sure!) created and launched best-selling game titles like F-15 Strike Eagle, F-117A Stealth Fighter, Gunship, Silent Service, Tom Clancy’s Red Storm Rising (the game), Pirates!, Railroad Tycoon, Civilization and many more.

[Quik18holes]

This board needs my "Easy POPS"!! IGSM, IENT, TFZI, MUTM!!

[InvestorSuisse]

DGIT Bouncing! $37.00 entry

[InvestorSuisse]

On watch!

[BULLISH_TRADER]

POPN .0009 radar for a bounce

[langlui]

SREH / ICOA / SNDY

[InvestorSuisse]

COCO taking off

[InvestorSuisse]

Apple's iPhone 4 hits stores TODAY

http://www.cnn.com/2010/TECH/mobile/06/24/iphone.4/index.html?hpt=C1

[BULLISH_TRADER]

$$$$ OWVI DAILY CHARTS $$$$

[InvestorSuisse]

NMT Medical, Incorporated is Dramatically Oversold after CLOSURE Trial Data

Shares of NMT Medical, Inc. (NASDAQ: NMTI), a medical device company that designs, develops, manufactures and markets proprietary implants that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures were dramatically oversold after its CLOSURE I using the STARFlex technology failed to meet its primary endpoint. The trial data failed to show superiority to current medical therapy for preventing recurrent strokes and TIAs. This may or may not be the end of the line for the STARFlex technology at least for the CLOSURE I application. However, there is much more to this company than this one device.

Most importantly is the CE Mark it has already earned in Europe for its CardioSEAL technology in 1996. The CardioSEAL is a catheter delivered cardiac implant device designed to close holes in the heart. In 2002, they received premarket approval (PMA) from the U.S. Food and Drug Administration allowing commercial sale of the company's CardioSEAL cardiac septal repair implant in the United States for patients with ventricular septal defects (VSD) that are not candidates for surgical closure. NMT Medical has already gotten its foot in the door in Europe and at least their toes in the door in the United States so their future, it appears, is not dependent on the CLOSURE I product that has a lot of questions to be answered about it before it can continue.

Additionally, please note the closing comment CEO Frank Martin made today when announcing the trial data results: "We are continuing to develop the next generation of bioabsorbable implants, including our BioTREK™ device. In addition, we should note that the results of CLOSURE I have no impact on the status of our current FDA and CE Mark approvals for ventricular septal defect (VSD) and atrial level shunt patients.”

Please view the 52-week chart as well as the 5-year chart on NMTI, and you will note that the stock is now trading well below most points except in parts of 2008. The selloff on June 18th was way overdone, and the price should recorrect back to the $1 range over the next few weeks, if not days.

Additonal information on their STARFlex, CardioSEAL as well as their BioSTAR technologies can be viewed on their website at http://www.nmtmedical.com/technology.aspx?id=206. Remember to do your own DD before purchasing any stocks and note that I have a long position in NMTI. Good luck and please utilize NMTI as a long-term investment and not only a short-term trade. There should and will be many other clinical trial results and approvals coming out of NMT Medical, and I will be anxiously awaiting all of them. Heart disease is a leading killer worldwide, and NMT Medical is equiping the medical device field with good options for several types of heart defects and injuries. The revenue stream should begin increasing as these product are marketed, partners are found or a buyout takes place.

http://seekingalpha.com/instablog/399559-chemistfrog/77299-nmt-medical-incorporated-is-dramatically-oversold-after-closure-trial-data

Disclosure: Please note that the author has a long position in NMTI
Themes: Medical Devices Stocks: NMTI

[InvestorSuisse]

Heck yeah 2.80 to 0.60 should be profit enough for the shorts. They better cover soon to keep such nice gains imo.

[NYPharmer1]

completely overexaggerated ! Shorts should be covering soon as well.

[InvestorSuisse]

NMTI- I think the drop was over exaggerated and that we should see a nice bounce this am.

[InvestorSuisse]

Thanks NYPharmer!

[NYPharmer1]

:) Favorite - nice forum!

[littlefeets]

WNBD DD Site;

http://sites.google.com/site/wnbdwinningbrands/home

[J A W]

WNBD. News out after close. DRTV campaign rolling. Orders confirmed from Discovery Health, Family NEt, Halmark Movie Channel. Product to hit shelves in Western Canadian Pharmacies.

Give it a look.

[Hedge Starz]

http://www.microcapreports.com/hbrm-herborium-group-experience-counts-and-the-company-has-plenty-to-share/
http://investorshub.advfn.com/boards/board.aspx?board_id=8226

[InvestorSuisse]

PEIX on Watch!

[InvestorSuisse]

EEE (.12) ***TRADE ALERT*** Evergreen Energy Receives Positive Court Decision
Jun 9, 2010 2:15:00 AM
Copyright Business Wire 2010

http://stockcharts.com/h-sc/ui?s=EEE&p=D&yr=0&mn=6&dy=0&id=p93095886049&a=179665325&listNum=1


DENVER--(BUSINESS WIRE)-- Evergreen Energy Inc. (NYSE Arca:EEE), a green energy technology solutions company, received a favorable ruling from the Court of Common Pleas Columbiana County, Ohio in the litigation commenced by certain holders of our outstanding 2007 Convertible Notes against Buckeye Industrial Mining Co., the Company and the holders of the 2009 Notes, AQR Absolute Return Master Account L.P., et al., v. Centurion Credit Funding LLC, Level 3 Capital Fund, LP, Buckeye Industrial Mining Company, et al., Case No. 10CV340 (Ct. Com. Pl. Columbiana County, OH). The favorable ruling provides: First, that the temporary restraining order currently preventing the company from transferring approximately $2.5 million of the proceeds from the sale of certain Buckeye assets and certain assets of the company will be lifted effective at 4:00 p.m. EDT on June 11, 2010. Second, the Court denied a further request to (i) restrain the transfer of these proceeds, (ii) restrain the recovery and use by the company of approximately $5 million in cash collateral backing certain environmental reclamation bonds, and (iii) place certain other restrictions upon the company and its subsidiaries.

This ruling clears the way for the company to collect and use approximately $7.5 million of proceeds from the Buckeye sale to retire certain trade debts and to support its working capital needs. Further, the ruling places no new restrictions on approximately $2.7 million of proceeds from the sale, currently held in escrow to cover indemnification claims from the buyer, which are scheduled to be released to Evergreen on March 31, 2011.

"We are pleased that the Court agreed with our position that judicial restrictions on the company's use of the proceeds from the Buckeye asset sale were not warranted," said Thomas H. Stoner, Jr., CEO and director of Evergreen. "We intend to employ the excess funds that become available to the company for working capital purposes. The efforts to sign a commercialization agreement for K-Fuel(R) are moving ahead, and to address next steps we are deploying additional engineering resources to China. Also, we continue our GreenCert(TM) product development, focusing on advanced technology including Cloud-based architecture. These accomplishments combined with our improved first quarter operations position us well for the second half of 2010. In fact, illustrating confidence in our business plan, members of our board and the management team have recently purchased Evergreen common stock."

Although the Court has issued a ruling in favor of the Company, the merits of the litigation have not been resolved.

Evergreen Energy Inc.

Evergreen Energy Inc. (NYSE Arca: EEE) has developed two proven, proprietary, patented, and transformative green technologies: the GreenCert(TM) suite of software and services and K-Fuel(R). GreenCert, which is owned exclusively by Evergreen, is a scientifically accurate, scalable environment intelligence solution that measures greenhouse gases and generates verifiable emissions credits. K-Fuel technology significantly improves the performance of low-rank coals yielding higher efficiency and lowering emissions. Visit www.evgenergy.com for more information.

Safe Harbor Statement

Statements in this release that relate to future plans or projected results of Evergreen Energy Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended by the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), and Section 21E of the Securities Exchange Act of 1934, as amended by the PSLRA, and all such statements fall under the "safe harbor" provisions of the PSLRA. Our actual results may vary materially from those described in any "forward-looking statement" due to, among other possible reasons, the realization of any one or more of the risk factors described in our annual or quarterly reports, or in any of our other filings with the Securities and Exchange Commission, all of which filings any reader of this release is encouraged to study. In addition, our ability to execute our business plan and develop the GreenCert(TM) or K-Fuel(R) technologies may be adversely impacted by an unfavorable decisions in the Buckeye litigation, which could result in a damage award against the Company, adversely impacting our ability to utilize the proceeds received from the sale of Buckeye, raise significant additional capital or effectively complete any restructure transaction on a timely basis to fund our business operations. Readers of this release are cautioned not to put undue reliance on forward-looking statements.




Source: Evergreen Energy Inc.


----------------------------------------------
Evergreen Investor Contact:
Lippert / Heilshorn & Associates
Kirsten Chapman & Becky Herrick
415-433-3777
[e-mail]

[Hedge Starz]

http://www.microcapreports.com/hbrm-herborium-group-experience-counts-and-the-company-has-plenty-to-share/
http://investorshub.advfn.com/boards/board.aspx?board_id=8226


Big volume hitting HBRM today. Looking good for a nice run here.

[InvestorSuisse]

Aeterna Zentaris to Present at Upcoming Needham Annual Healthcare Conference on June 10, 2010
Last update: 6/2/2010 7:30:00 AM
QUÉBEC CITY, June 2, 2010 /PRNewswire via COMTEX/ -- Aeterna Zentaris Inc. (AEZS)(CA:AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that its President and CEO, Juergen Engel, Ph.D., will present a corporate overview at the upcoming 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010 at 3:20 p.m. (local time) in the Henry Room of the New York Palace Hotel in New York City.
A live webcast of the presentation will be available on Aeterna Zentaris' website at in the Investors section. A replay will also be available for a period of 30 days on the Company's website.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at .
SOURCE AETERNA ZENTARIS INC.
Copyright (C) 2010 PR Newswire. All rights reserved

[AliAngel]

Hey bull I got your message and I am on the free plan for now. I am busy running the road for the rest of the summer and will be on board only occasionally. Freight is paying better then ever before and going to make the hay when the sunshines.
This winter I will be off again and back to trading for a couple of months.
Will check in time to time when not worn out.
Dave

WOLV Here is a nice one going into next week for sure. This will be a dollar plus in a year.

[InvestorSuisse]

AEterna Zentaris (AEZS) is a undiscovered biotech company with multiple pahse III,
phase II, phase I and several promising preclinical cancer drugs. They have almost
no debt ($300k), $40mln cash, only 115mln mcap with low $6 mln cash burn.

Over 45% of shares are held by institutions/mutal funds and insiders:
http://www.dailyfinance.com/company/aete...

Recently published article, AEZS - Uncovering the next dominant cancer company
http://www.themarketfinancial.com/aetern...

Do your own DD. Link to latest AEteran presentation from May 2010:
http://www.aeternazentaris.com/pdfdyn/Pr...

Check out AEterna's pipeline of drugs:
http://www.aeternazentaris.com/en/page.p...


Perifosine, first-in-class oral AKT inhibitor
Multiple Myeloma (phase III)
Advanced Colorectal Cancer ( phase III to start soon)
Kidney Cancer (phase II)
and Others
/ AEZS licensed N.American rights to KERX, which pays for trials costs and 11% royalties
of potential futures sales. AEZS is holding the rights for rest of world, wich is as big
as north american market excluding South-Korea.

AEZS-108
Endometrial Cancer (phase II, final results end of 2010)
Ovarian Cancer (phase II, final results end of 2010)
Bladder Cancer (phase II start end of 2010)
Other Cancers

AEZS-112 (phase I)
Solid Tumor

AEZS-120 *Tumor Vaccine, (pre-clinical), phase I start in mid to second half of 2010
/ similar to DNDN's Provenge
Prostate Cancer

AEZS-129/131PI3K/ErkInhibitor (pre-clinical)
/ Similar to Ariads ridaforolimus, licensed to Merck for up to $500mln


AEZS-127 Intravenous administrionable Perifosine
And here is AEZS masterplan:

Once KERX does pays all the trials for Perifosine and the drug succeeds, AEZS will present
Perifosine II, intravenous injectable and thus very likely more efficient Perifosine:

AEZS-127 (Erucylphosphocholine (ErPC)) is an analog of perifosine which is suitable for
intravenous administration. Like perifosine, AEZS-127 belongs to a new class of compounds
based on alkylphosphocholines that Æterna Zentaris has developed in our Drug Discovery group.
AEZS-127 possesses distinctive reduced hemolytic activity thus allowing for intravenous injection.
Æterna Zentaris owns the worldwide rights.



Cetrotide®
(Marketed by Merck Serono, Nippon Kayaku / Shionogi (Japan))
In VitroFertilization, AEterna gets around $6 mln per quarter

AEZS-130 (SolorelTM)
Diagnostic – Adult Growth Hormone Deficiency, phase III

AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia,
a condition which results in a severe reduction of muscle mass and weight loss in
patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS
and certain cancers. Potential update in 2010.

AEZS-130 (macimorelin) - Phase I
Therapeutic

AEZS-123Ghrelin Antagonist - Preclinical
EndocrinologyPartners:



Because of incredible low valuation, AEZS is listed as top acquisition target:

http://finance.yahoo.com/news/Brean-Murr... xpert-twst-1880440369.html?x=0&.v=1
http://finance.yahoo.com/news/60-Premium...

Mootley Fool says, a buyout and bidding war could indeed come:
http://www.fool.com/investing/high-growt...


IMO, based on AEterna's great pipeline of late stage cancer drugs, she should be trading
well over $8 and could be taken over for $15 per share. I think, AEZS is a multi-bagger
and worth doing your own DD. If there's no buyout and Perifosine is marketed, AEZS could
be a 100-bagger, a 10.000% chance.

[InvestorSuisse]

Æterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in Neuroblastoma Tumors

http://finance.yahoo.com/news/terna-Zentaris-Publication-in-prnews-1577878739.html?x=0&.v=1

[InvestorSuisse]

Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency

http://finance.yahoo.com/news/Aeterna-Zentaris-Receives-prnews-2019644518.html?x=0&.v=2

[InvestorSuisse]

Canaccord ups AEterna price target

Canaccord Genuity has raised its price target on “speculative buy-rated” AEterna Zentaris (AEZS 1.86 ?6.06%) (NASDAQ:AEZS; TSX:AEZ (1.91 ?2.55%)) to $2.60 (U.S.) from $1.65 after updating its valuation to include the colorectal cancer indication for the company’s perifosine drug.

In a new report, analyst Neil Maruoka says he figures perifosine will have peak revenues of $400 million treating colorectal cancer and gives the drug a 55% probability of clinical success. That’s the same probability that he projects for perifosine’s multiple myeloma indication.

The drug has advanced into Phase 3 studies in multiple myeloma and colorectal cancer, and “we believe that results from these studies will be major drivers for the stock,” he added.

http://biotuesday.ca/2010/05/14/canaccord-ups-aeterna-price-target/

[InvestorSuisse]

AEZS>$2.09 AEterna Zentaris reports Q1 EPS (-9c) vs. consensus of (-12c)
Reports Q1 revenu $6.42M vs. consensus of $6.17M

[InvestorSuisse]

iGo® Slim Laptop Wall Charger Now Available in Walmart Stores Nationwide

iGo (Nasdaq:IGOI), a leading provider of eco-friendly power management solutions, is rolling out the iGo Slim Laptop Wall Charger to more than 3,000 Walmart stores across the United States. Retailing for $74.88, the ultra-slim and light iGo charger can power virtually all laptops sold today.

“Following a successful trial program, we are very pleased to roll out our Slim Laptop Wall Charger to Walmart stores across the United States,” said Michael D. Heil, President and Chief Executive Officer of iGo. “Our charger meets the demand for lighter, eco-friendly power solutions at a low price, and we believe it provides a great value to Walmart customers.”

As with all iGo chargers, the Slim Laptop Wall Charger uses iGo’s intelligent tip technology, which allows consumers to continue using the same charger for each new laptop they purchase in the future. By simply changing the power tip on their charger, consumers can reuse the same charger over and over again, saving money and reducing e-waste in the process.

About iGo, Inc.

iGo, Inc., based in Scottsdale, Arizona, is a leading provider of power management solutions, including eco-friendly chargers for laptop computers, netbooks and mobile electronic devices (e.g., mobile phones, PDAs, digital cameras, etc.). All of these chargers leverage iGo’s intelligent tip technology, which significantly minimizes electronic waste by enabling one charger to charge hundreds of brands and thousands of models of mobile electronic devices through the use of interchangeable tips. iGo is also the creator of a new, innovative patent-pending, power-saving technology that automatically eliminates virtually all wasteful and expensive standby or “vampire” power that is generated from chargers that continue to draw electricity when a mobile electronic device no longer requires charging or is disconnected from the charger.

iGo’s products are available at www.iGo.com as well as through leading resellers and retailers. For additional information call 480-596-0061, or visit www.igo.com.

iGo is a registered trademark of iGo, Inc. All other trademarks or registered trademarks are the property of their respective owners.

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. The words “believe,” “expect,” “anticipate,” “should,” and other similar statements of expectations identify forward-looking statements. Forward-looking statements in this press release include the belief that the Company’s chargers provide a great value to Walmart customers. These forward-looking statements are based largely on management’s expectations and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks that could cause results to differ materially from those expressed in these forward-looking statements include, among others, the timing and success of product development efforts and new product introductions, including internal development projects as well as those being pursued with strategic partners; the timing and success of product developments, introductions and pricing of competitors; the timing of substantial customer orders; the availability of qualified personnel; the availability and performance of suppliers and subcontractors; the ability to expand and protect the Company’s proprietary rights and intellectual property; the successful resolution of unanticipated and pending litigation matters; market demand and industry and general economic or business conditions; and other factors to which this press release refers. Additionally, other factors that could cause actual results to differ materially from those set forth in, contemplated by, or underlying these forward-looking statements are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009 under the heading “Risk Factors.” In light of these risks and uncertainties, the forward-looking statements contained in this press release may not prove to be accurate. The Company undertakes no obligation to publicly update or revise any forward-looking statements, or any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Additionally, the Company does not undertake any responsibility to update you on the occurrence of unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

[langlui]

no news yet.. but all bios seems to be running again, lots of them are up in premarket

[InvestorSuisse]

Thanks Langlui!

Whats going on with this stock? Looks very Bullish!

[langlui]

DRAD for today, strong

[InvestorSuisse]

Bull Watch-
HNAB- Solid DD play going into ASCO

SCLN- Bouncer
EXEL- Bouncer

[InvestorSuisse]

Cytori Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump. Based on positive safety and feasibility outcomes, and the biological, physiological and functional effects from this pilot study, plans are underway by Cytori Therapeutics (NASDAQ: CYTX), the trial sponsor, to initiate a European medical device approval study for the Celution® System, the cell processing system used in the study. More detailed information on this study and the results from a separate study in chronic heart disease patients may be found at the following link: cytoritx.presslift.com/cardiacdata.

Six-month results from the 14 patient, double-blind, placebo controlled study, referred to as the APOLLO trial, were reported today by Henrickus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital and co-Principal Investigator for the trial, at the 7th International Symposium on Stem Cell Therapy & Cardiovascular Innovation in Madrid, Spain. Highlights of the study’s six month outcomes are as follows:

The Celution® System-based procedure could be safely performed in an acute setting with no side effects from cell delivery, and no increase in arrhythmias

The study showed a 13.3% absolute reduction in the left ventricular infarct size (the portion of the heart not receiving blood to support pumping) in the treated group versus 8.2% in the placebo group from baseline to six months, based on blinded assessment of MRI data by an independent core laboratory. These data represent matched-pair analysis and exclude two patients whose follow up MRIs were not available. For the entire cohort of patients, mean infarct size improved from 31.6% at baseline to 15.4% at 6 months in cell-treated patients, and remained unchanged at 24.7% in the placebo group. The relevance of this reduction is that based on published literature, patients with an infarct size below 18% have a significantly lower risk of major adverse cardiac events (MACE) than those who are above this level
There was a 3.5 fold greater improvement in perfusion within the left ventricle in the cell treated group (6.0) compared to the placebo group (1.7), as measured by SPECT Visual Rest Scores (nuclear imaging of the heart)
Ejection fraction was measured by four imaging modalities. The greatest absolute change was found in the SPECT (single photon emission computed tomography) analysis, which showed a 5.7% absolute improvement in the cell treated group (+4.0%) compared to placebo (-1.7%)
“Improvements in infarct size, perfusion and ejection fraction are reflective of improvement in the overall cardiovascular health of a patient,” said Dr. Duckers. “Infarct size in particular, based on emerging consensus by the medical community and literature, is what we believe to be the most important predictor of re-hospitalization for heart failure, subsequent infarct, and death. The outcomes from this study are very exciting and warrant moving into a pivotal trial for European approval.”

“The clinical data from APOLLO is consistent with Cytori’s comprehensive preclinical data, reinforcing that improved blood flow and reduction of infarct size are how these cells are believed to impart benefit,” said Marc H. Hedrick, M.D., president of Cytori. “Compared to other cell sources, adipose tissue, using the Celution® System, is the only approach whereby a patient can access a meaningful number of their own cells at the point-of-care. This is especially critical for heart attack patients, where successful outcomes are dependent on immediate coronary intervention.”

As part of the novel procedure, a small amount of fat tissue was removed from each patient’s abdomen shortly after his or her heart attack. Using a proprietary medical device, the Celution® System, developed by Cytori, stem and regenerative cells were quickly separated from each patient’s fat tissue and concentrated at the point-of-care in the catheter laboratory. The cells were then immediately injected into the patient’s coronary artery. Liposuction, processing, and cell delivery all took place within the same procedure.

The APOLLO study is led by co-Principal Investigators Patrick W. Serruys, MD, PhD, Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital and Henrickus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital. Hospital General Universitario Gregorio Marañón in Madrid, led by Francisco F. Avilés M.D., PhD, Professor of Medicine and Chief of Department of Cardiology, also participated in this study.

“We would like to thank the patients, the investigators, and all who collaborated with us on this trial,” added Alex Milstein, M.D., Vice President of Clinical Development at Cytori. “We are working closely with our Notified Body in Europe to finalize the design and protocol for a pivotal heart attack study, which we expect to initiate in late 2010 to early 2011. This will be a European approval study that is expected to range in size from 150 to 250 patients.”

[InvestorSuisse]

May 2010 Shareholder Letter

First Quarter 2010 Results and Commercial and Clinical Update

Dear Shareholders,
The first quarter of 2010 was very strong for Cytori. In particular, we substantially grew product revenues, shipped more consumables per quarter than ever, launched a new product platform in the U.S. and completed several important objectives related to our pipeline.
Today, Cytori sells differentiated and proprietary products to the private-pay cosmetic surgery markets within the U.S., Europe, and Asia as well as innovative equipment for cell banking and research. In parallel, we are laying the foundation for future growth through advancements in our pipeline of therapeutic applications for our core product, the Celution® System. Celution® has been used by our physician customers to treat many debilitating or fatal medical conditions such as cardiovascular disease, non-healing and recalcitrant wounds from radiation injury, urinary incontinence and others.
Despite the breadth of diseases represented in this limited list above, there is a clear common thread connecting them all. That thread is ischemia. In these diseases, as well as many others, Cytori’s technology helps patients by improving tissue ischemia or low blood supply conditions. Adipose-derived stem and regenerative cells (ADRCs) have unlimited potential in a large number of diseases by improving blood supply to tissues that would otherwise remain ischemic (or blood starved). When added to adipose tissue, ADRCs improve survival of this natural filler by improving blood supply and enhancing the flow of oxygen and nutrients. When ADRCs are administered directly into the diseased heart, ischemia is improved, based on a comprehensive portfolio of basic and preclinical research. This common mechanism of action of ADRCs formed the basis for Cytori’s RESTORE 2 study that has completed enrollment in Europe as well as two Cytori sponsored cardiovascular studies that have been accepted for presentation at two forthcoming scientific meetings. Furthermore, a growing number of physicians around the world are further expanding the use of Cytori technology with investigator sponsored clinical studies.
Product Sales
In the first quarter, product revenues were $2.3 million, representing 19% growth over Q1 2009 product revenues of $1.9 million and 80% growth over the 4th quarter 2009. Revenues grew from a mix of Celution® and StemSource® sales in Europe, Asia and the U.S. and the move toward increased direct sales. Growth of consumable reorders reflects the established base of satisfied customers who are increasingly integrating Celution® into their practices. We also achieved our second StemSource® Cell Bank installation in Japan, which was ordered by one of our existing Celution® customers to meet growing patient demand to store their own stem cells following liposuction for subsequent cosmetic procedures.
The cumulative number of revenue generating systems grew to 110 in the quarter, compared to 59 at the end of the first quarter of 2009. In addition, 342 consumables, including 261 re-orders, were shipped, compared to 241 total consumables shipped in Q1 2009, 164 being reorders. More than 2,300 cumulative consumables have been shipped since commercialization began in Q1 2008.
Product Pipeline and Future Growth
Cosmetic and Reconstructive Surgery
Near term sales growth will come through a combination of increased sales of existing products including Celution®, StemSource® and PureGraft® for cosmetic and research applications as well as emerging consumable sales for use in breast reconstruction. Our FDA cleared PureGraft® product was launched at the American Society of Aesthetic Plastic Surgery meeting in Washington D.C. last week. More information on this unique product can be found on our newly introduced PureGraft® e-commerce site at www.puregraft.com. We anticipate EU approval on PureGraft® soon and expect this will contribute to sales growth increasingly throughout 2010.
Currently, reconstructive surgery represents only a fraction of overall consumable sales. We believe that 12 month data from RESTORE 2 will significantly expand our ability to obtain third party and governmental reimbursement, supporting increased adoption in that market. Well in advance of RESTORE 2 data release, Cytori has begun to expand its price negotiation and reimbursement efforts in Europe, focused principally on two areas. First, we are obtaining key opinion leader support for Cytori technology specifically in the Italian and U.K. markets. In addition, we are accelerating our direct lobbying efforts to third party payers and governmental gate keepers responsible for reimbursement decision making. Significant progress is being made in both markets and we will keep you updated as we achieve key milestones.
Interventional Cardiology
Tomorrow, May 7th, Cytori investigators will report results from our two cardiac clinical trials: APOLLO for acute myocardial infarction (heart attack) and PRECISE for chronic myocardial ischemia, a severe form of chronic heart disease. Specifically, these results will be presented at the 7th International Symposium on Stem Cell Therapy and Cardiovascular Innovations in Madrid, Spain. Following the presentation of these results, we will address possible next steps in this area.
U.S. Regulatory Approval for the Celution® System
Obtaining U.S. approval for Celution® is a major goal for Cytori. A Pre-IDE meeting with the FDA is scheduled this month to define clinical objectives needed for Celution® approval for soft tissue reconstruction. We anticipate that our next opportunity to update investors on this U.S. application will be upon the acceptance of our IDE application, which would signify that the FDA has agreed to our trial design.
In the meantime, we intend to rapidly grow U.S. sales of our PureGraft® and StemSource® products. This benefits today’s top line growth and helps Cytori build key U.S. physician relationships and product awareness as well as strengthen our position as the clear leader in the field.
‘Cytori’s Innovation Partners’ and New Uses of Cytori Technology
Regenerative medicine is a new and exciting field of medicine. As a result, many physician researchers want safe, clinical-grade cells to restore the lives of their patients. This is a common theme we hear each week. As a result, many hospitals around the world are conducting independent investigator-initiated studies using the Celution® System for indications as diverse as urinary incontinence, cardiomyopathy, renal failure, liver disease, radiation injury and burns. The value that our ‘innovation partners’ bring is undeniable. In fact, RESTORE I, a breast cancer reconstruction study, is the first example of the value of this opportunity that has led to our first potential U.S. indication for Celution®.
In short, Celution® is an ‘innovation platform’ as much as a therapeutic medical device. This aspect of our business is a critical strategic advantage for the Company. By outsourcing the early clinical development to expert clinicians in this way, we cost effectively accelerate our clinical development program and create greater opportunities to take key indications directly to market or to establish strategic partnerships.
Operating Results
We generated a substantial increase in gross margin. Gross margin increased to 59% in the first quarter 2010 compared with 43% in the first quarter 2009. The improvement in margin is due largely to a greater proportion of direct sales and improved manufacturing efficiencies.
While aggressively driving sales, we continue to control our expenses. Total operating expenses were effectively unchanged compared to the first quarter of 2009, excluding the non-cash change in warrant and option liabilities. We also substantially improved our balance sheet, ending the first quarter with $22.7 million in cash and cash equivalents compared to $12.9 million at the end of 2009. Subsequent to the end of the quarter, we raised an additional $2.3 million from the sale of stock through our committed equity agreement with Seaside 88, LP.
Summary
In our 2009 year end shareholder letter, I mentioned our 3 core objectives for 2010 and I would like to summarize them: 1) expand our cosmetic and reconstructive surgery related sales, 2) advance our core pipeline applications and 3) establish a substantive partnership. The first quarter of 2010 represents a very strong start to the year. We are confident in continued sales growth for the remainder of 2010, with clinical outcomes to be reported from our APOLLO and PRECISE cardiovascular trials this week. The increased visibility provided by both sales growth and the reporting of key clinical data provide a basis for advancing discussions with potential partners.
Thank you for your interest in Cytori and we look forward to keeping you updated on our growth and progress.
Warm Regards,

Christopher J. Calhoun
Chief Executive Officer

Cautionary Statement Regarding Forward-Looking Statements
This shareholder letter includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our forecasts for 2010 operating expenses and cash utilization rate, future growth through advancements in our pipeline of therapeutic applications for our core product, the Celution® System, our sales expectations, including those from our marketing and distribution partners, the continued growth of investigator clinical trials using our technology, system and consumable order trends, our ability to obtain EU approval and successfully commercialize the PureGraft™ product, as well as our ability to obtain third party and governmental reimbursement for our consumables and therefore increase adoption in the reconstructive surgery market, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, as well as other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form10-K and 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

[InvestorSuisse]

Cytori Reports First Quarter Results

Cytori Therapeutics (NASDAQ:CYTX) is reporting its first quarter financial results. More information on our commercial and clinical progress is posted online in the 'May 2010 Shareholder Letter' at http://ir.cytoritx.com.

Key accomplishments for Cytori in the first quarter and year-to-date include the following:

Continued growth in Celution® and StemSource® System and consumables sales
Sale and installation of a StemSource® Cell Bank in Japan
FDA clearance (Q1) and US launch (Q2) of the PureGraft™ autologous fat grafting system
Gained further clarity from the FDA on US regulatory pathway for the Celution® System
Systems and Consumables

In the first quarter of 2010, Cytori increased its cumulative number of 'revenue systems’ (those sold directly to physicians, distributors or placed, which are generating consumable sales) to 110, compared to 59 at the end of the first quarter of 2009 and 101 at the end of the prior quarter.

In addition, 342 consumables were shipped in the first quarter of 2010, compared to 337 consumables shipped in the fourth quarter of 2009 and 241 consumables shipped in the first quarter of 2009. Of these, 261 consumables were re-orders in the first quarter of 2010, compared to 164 re-orders in the same quarter of 2009 and 258 re-orders in the prior quarter. More than 2,300 cumulative consumables have been shipped to date since commercialization began in Q1 2008.

System & Consumable Order Trends


Q1 2010 Q4 2009 Q1 2009
Revenue Systems (Cumulative) 110 101 59
Consumables Shipped 342 337 241
Consumable Re-orders 261 258 164


Financials

Total revenues for the first quarter of 2010 were $4.4 million, which consisted of $2.3 million in product revenue from Celution® and StemSource® sales in Europe, Asia and the United States and $2.1 million in development revenue. This compares to $1.9 million in total revenues in the first quarter of 2009, of which all $1.9 million were attributable to product sales. Gross margin was 59% with a gross profit of $1.3 million, up from 43% with a gross profit of $0.8 million in the first quarter of 2009.

Total operating expenses were $5.6 million, compared to $6.4 million in the first quarter of 2009. Included in operating expenses was a $1.9 million net reduction in non-cash change in fair value of the warrant and option liability compared to a $0.8 million net reduction in the first quarter of 2009.

Cytori ended the quarter with $22.7 million in cash and cash equivalents plus $2.7 million in accounts receivable, net. Subsequent to end of the quarter, Cytori raised an additional $2.3 million from scheduled sales of its common stock under its current financing arrangement with Seaside 88, LP.

Conference Call & Shareholder Letter

Cytori will host a conference call and question and answer session at 10:30 a.m. Eastern Time today to further discuss these results. The audio webcast of the conference call may be accessed under "Webcasts" in the Investor Relations section of the Cytori's website (www.cytori.com). The webcast will be available live and by replay two hours after the call and archived for one year. More information on our commercial and clinical progress is posted online in the 'May 2010 Shareholder Letter' at http://ir.cytoritx.com.


http://www.dailyfinance.com/rtn/pr/cytori-reports-first-quarter-results/rfid326550300/?channel=pf

[InvestorSuisse]

I'm expecting CYTX to trade really nicely this week going into Friday. With all of the buying within the last 10 minutes of the market being open yesterday, I'm betting today will be a blast imho.

[InvestorSuisse]

Good morning everyone~

[InvestorSuisse]

Good Morning Everyone~

[langlui]

you are welcome. Looks like some of them are getting diluted, but pigs do run u know... Oh i forgot FNXCE!

[InvestorSuisse]

Thanks langlui, I just put them on the watch list!

[langlui]

Thanks. I stole the info already :P Watch NUBL MTCHE ICBT HESV IGSM all bottom bounce potential.

[InvestorSuisse]

I fellow ihubber had posted it on another board langlui, so I thought I'd post it over here for everyone to see. Very important/ useful information imho.

[InvestorSuisse]

CYTX is looking good!